<DOC>
	<DOCNO>NCT00115167</DOCNO>
	<brief_summary>The purpose study determine safety darbepoetin alfa beyond 16 week treatment subject anemia cancer receive chemotherapy .</brief_summary>
	<brief_title>A Study Darbepoetin Alfa Anemic Subjects Not Receiving Chemotherapy Who Have Completed 20010103 Study</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects complete plan 16 week treatment 20010103 Anemia Cancer protocol Subjects currently receive plan receive cytotoxic chemotherapy myelosuppressive radiotherapy Subjects diagnose related cancer cause anemia Known history seizure disorder Cardiac condition : uncontrolled angina , congestive heart failure , know ejection fraction le 40 % , uncontrolled cardiac arrhythmia Uncontrolled hypertension Clinically significant systemic infection chronic inflammatory disease present time enrollment Subject reproductive potential use adequate contraceptive precaution Concerns subject 's compliance protocol procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Oncology</keyword>
	<keyword>Cancer-related anemia</keyword>
</DOC>